Diabetes, Obesity and Metabolism

Glucagon antagonism as a potential therapeutic target in type 2 diabetes
pp. 965-971(7)
Authors: Bagger, J. I.; Knop, F. K.; Holst, J. J.; Vilsbøll, T.

Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials
pp. 972-981(10)
Authors: Wang, Y.; Li, L.; Yang, M.; Liu, H.; Boden, G.; Yang, G.

Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study
pp. 982-989(8)
Authors: Berg, J. K.; Shenouda, S. K.; Heilmann, C. R.; Gray, A. L.; Holcombe, J. H.

GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice
pp. 990-1000(11)
Authors: Jolivalt, C. G.; Fineman, M.; Deacon, C. F.; Carr, R. D.; Calcutt, N. A.

Short-term metabolic effects of prednisone administration in healthy subjects
pp. 1001-1007(7)
Authors: Kauh, E. A.; Mixson, L. A.; Shankar, S.; McCarthy, J.; Maridakis, V.; Morrow, L.; Heinemann, L.; Ruddy, M. K.; Herman, G. A.; Kelley, D. E.; Hompesch, M.

Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis
pp. 1008-1019(12)
Authors: Pontiroli, A. E.; Miele, L.; Morabito, A.

Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month `proof-of-concept' study
pp. 1020-1027(8)
Authors: Owens, D. R.; Luzio, S. D.; Sert-Langeron, C.; Riddle, M. C.

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study
pp. 1028-1035(8)
Authors: Kaku, K.; Itayasu, T.; Hiroi, S.; Hirayama, M.; Seino, Y.

A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-na
pp. 1036-1046(11)
Authors: Borges, J. L. C.; Bilezikian, J. P.; Jones-Leone, A. R.; Acusta, A. P.; Ambery, P. D.; Nino, A. J.; Grosse, M.; Fitzpatrick, L. A.; Cobitz, A. R.

Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia
pp. 1047-1055(9)
Authors: Gumprecht, J.; Gosho, M.; Budinski, D.; Hounslow, N.

Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus
pp. 1056-1058(3)
Authors: Gustavson, S. M.; Chen, D.; Somayaji, V.; Hudson, K.; Baltrukonis, D. J.; Singh, J.; Boyden, T. L.; Calle, R. A.

News and views
pp. 1059-1061(3)
Author: Idris, Iskandar